Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 3/2012

01-03-2012 | Original Article

FDG-PET in the Erdheim–Chester disease: its diagnostic and follow-up role

Authors: Emőke Šteňová, Boris Šteňo, Pavol Povinec, František Ondriaš, Jana Rampalová

Published in: Rheumatology International | Issue 3/2012

Login to get access

Abstract

A 62-year-old man presented with diabetes insipidus, pulmonary fibrosis, right atrial tumor and bilateral knee osteoarthritis with cystic lesions of distal femur and proximal tibia. Scintigraphy and histological examination of right femur bone biopsy revealed changes characterized for Paget’s disease. Re-evaluation of the computer tomography (CT) scans and histological samples revealed diffuse infiltrates of foamy histiocytes in the bone marrow what was consistent with Erdheim–Chester disease. Positron emission tomography/computed tomography (PET/CT) was performed to access the activity and extent of disease.
Literature
1.
Dickson BC, Pethe V, Chung CTS et al (2008) Systemic Erdheim-Chester disease. Virchows Arch 452(2):221–227PubMedCrossRef
2.
Haroche J, Amoura Z, Dion E et al (2004) Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore) 83(6):371–392CrossRef
3.
Chester W (1930) Ueber lipoidgranulomatose. Virchows Arch Pathol Anat 279:561–602CrossRef
4..
Haroche J, Amoura Z, Trad SG et al (2006) Variability in the efficacy of interferon-α in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arth Reum 54(10):3330–3336CrossRef
5.
Haroche J, Amoura Z, Wechsler B, Veyssier-Belot C, Charlotte F, Piette JC (2007) Erdheim-Chester disease. Presse Med 36:1663–1668PubMedCrossRef
6.
Sheidow TG, Nicolle DA, Heathcote JG (2000) Erdheim-Chester disease: two cases of orbital involvement. Eye 14:606–612PubMedCrossRef
7.
Na SJ, Lee KO, Kim JE, Kim YD (2008) A case of cerebral Erdheim-Chester disease with progressive cerebellar syndrome. J Clin Neurol 4(1):45–50PubMedCrossRef
8.
Jendro MC, Zeidler H, Rosenthal H, Haller H, Schwarz A (2004) Improvement of Erdheim-Chester disease in two patients by sequential treatment with vinblastine and mycophenolate mofetil. Clin Rheumatol 23(1):52–56PubMedCrossRef
9.
Bourke SC, Nicholson AG, Gibson GJ (2003) Erdheim-Chester disease: pulmonary infiltration responding to cyclophosphamide and prednisolone. Thorax 58(11):1004–1005PubMedCrossRef
10.
Myra C, Sloper L, Tighe PJ, McIntosh RS, Stevens SE, Gregson RH, Sokal M, Haynes AP, Powell RJ (2004) Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol 88(6):844–847PubMedCrossRef
11.
Otsuka Hideki, Morita Naomi, Yamashita Kyo, Nishitani Hiromu (2007) FDG-PET/CT for diagnosis and follow-up of vasculitis. J Med Invest 54:345–349PubMedCrossRef
12.
Pereira Neto CC, Roman C, Johnson M, Jagasia M, Martin WH, Delbeke D (2004) Positron emission tomography/computed tomography of a rare xanthogranulomatous process: Erdheim-Chester disease. Mol Imaging Biol 6(1):63–67PubMedCrossRef
Metadata
Title
FDG-PET in the Erdheim–Chester disease: its diagnostic and follow-up role
Authors
Emőke Šteňová
Boris Šteňo
Pavol Povinec
František Ondriaš
Jana Rampalová
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 3/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1676-y

Other articles of this Issue 3/2012

Rheumatology International 3/2012 Go to the issue

Original Article

Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope

Original Article

The effect of low-level laser to apoptosis of chondrocyte and caspases expression, including caspase-8 and caspase-3 in rabbit surgery-induced model of knee osteoarthritis

Original Article

Propylthiouracil-induced autoimmune syndromes: 11 case report

Letter to the Editor

A potential explanation of the reported low prevalence of hepatitis B virus infection in patients with systemic lupus erythematosus

Review

The association of Raynaud’s syndrome with carpal tunnel syndrome: a meta-analysis

Letter to the Editor

Osteonecrosis in SLE
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits